
Solving the development
and scale-up challenges of next-generation vaccines
To hear when each 2027 output is published
REGISTER YOUR INTERESTInterested in sponsoring the SIG?
FIND OUT MOREThe Vaccine Insights Special Interest Group (SIG) is an invitation-only initiative that brings senior experts together in small, closed-door working groups under the Chatham House Rule to build consensus, set priorities, and produce practical, open-access guidance for the field.
SIG members are invited from pharma, biotech, vaccine manufacturers, regulatory agencies, public health organizations, and academia to address one central question:
“What will it take to formulate, deliver, and manufacture the next generation of vaccines?”

COVID-19 showed how quickly new vaccine platforms can move from concept to global supply, but it also exposed the limits of current formulation, delivery, and manufacturing approaches. Lipid nanoparticles (LNPs) and adjuvants now underpin many next-generation candidates, from saRNA and combination vaccines to therapeutic cancer vaccines, yet stability, scale-up, analytical characterization, and supply remain persistent barriers. At the same time, advances in thermostable formulations, novel delivery routes, and platform and continuous manufacturing are changing what the field can realistically aim for, while biosecurity priorities and rapid-response targets are placing new demands on manufacturing capacity.
In its first year, the SIG will focus on four questions:
The full list of the Steering Committee and SIG members will be published in early 2027.
The SIG’s work in 2027 centers on a series of closed-door working groups, taking place from 1 to 19 November. The Vaccine Insights editorial team then turns the consensus reached by members into a series of outputs published in the months that follow, setting out the field’s shared position and priorities.
2027 annual SIG:
1–19 November
The SIG opens with a keynote presentation, followed by a series of working groups over three weeks. SIG members will meet in nine closed-door working groups under the Chatham House Rule, and each group will agree consensus statements on its topic.
Working groups:
All SIG members meet under the Chatham House Rule. Each working group will produce consensus statements, which will form the basis of the outputs below.
Results from live polls of SIG members during the meeting.
A full open-access meeting report with strategic recommendations for the field.
A peer-reviewed white paper on a priority topic identified by the group.
These may include webinars, articles, in-person SIG member gatherings, and report-outs at major vaccine conferences.
To be kept informed about the progression and development of the SIG outputs, please register your interest.
REGISTER YOUR INTEREST